FindTrial
Sign In

The values of assaying HPVE6/E7, STAT3, Survivin protein and mRNA in cervical canal secretions and exfoliated cells for cervical lesions screening

The values of assaying HPVE6/E7,STAT3,Survivin protein and mRNA in cervical canal secretions and exfoliated cells for cervical lesions screening

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012009
Enrollment
Unknown
Registered
2017-07-17
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the cervical disease

Interventions

Gold Standard:Taken cervical histological results as gold standard.Pathological diagnosis with a cervical (glandular)intraepithelial neoplasia (CIN/CGIN)? or greater was positive, CIN/CGIN? or lower w
Index test:HPVE6/E7,STAT3,Survivin

Sponsors

Department of Obstetrics and Gynecology, the Second People's Hospital of Changshou City
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 63 Years

Inclusion criteria

Inclusion criteria: (1) Have been examined by TCT and / or HR-HPVDNA genotyping; (2) No treatment history of cervical cancer and precancerous lesions; (3) non menstrual sampling; (4) No sexual life, vaginal examination, vaginal douche, and Vaginal topical medication within 72 hours .

Exclusion criteria

Exclusion criteria: (1) Havn't been examined by TCT and / or HR-HPVDNA genotyping; (2) treatment history of cervical cancer and precancerous lesions; (3) menstrual period; (4) Have sexual life, vaginal examination, vaginal douche, and Vaginal topical medication within 72 hours .

Design outcomes

Primary

MeasureTime frame
HPVE6/E7;STAT3;Survivin;—

Countries

China

Contacts

Public ContactYibing Fan

the Second People's Hospital of Changshou City

yibingfan@163.com+86 18662620089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026